2019
Availability of Grocery Delivery to Food Deserts in States Participating in the Online Purchase Pilot
Brandt EJ, Silvestri DM, Mande JR, Holland ML, Ross JS. Availability of Grocery Delivery to Food Deserts in States Participating in the Online Purchase Pilot. JAMA Network Open 2019, 2: e1916444. PMID: 31790562, PMCID: PMC6902750, DOI: 10.1001/jamanetworkopen.2019.16444.Peer-Reviewed Original Research
2018
Alirocumab’s Price Reduction
Dhruva SS, Ross JS, Desai NR. Alirocumab’s Price Reduction. Circulation 2018, 138: 1502-1504. PMID: 30354510, DOI: 10.1161/circulationaha.118.036069.Commentaries, Editorials and Letters
2017
The FDA Unapproved Drugs Initiative: An Observational Study of the Consequences for Drug Prices and Shortages in the United States.
Gupta R, Dhruva SS, Fox ER, Ross JS. The FDA Unapproved Drugs Initiative: An Observational Study of the Consequences for Drug Prices and Shortages in the United States. Journal Of Managed Care & Specialty Pharmacy 2017, 23: 1066-1076. PMID: 28944731, PMCID: PMC10397719, DOI: 10.18553/jmcp.2017.23.10.1066.Peer-Reviewed Original ResearchConceptsUnapproved Drugs InitiativeClinical evidenceAverage wholesale priceFDA approvalPrescription drugsNew clinical trial evidenceMedian shortage durationClinical trial evidenceNew clinical evidenceDrug shortagesNumber of drugsEvidence of safetyUtah Drug Information ServiceHealth-System PharmacistsHigh Prices for Drugs With Generic Alternatives: The Curious Case of Duexis
Hakim A, Ross JS. High Prices for Drugs With Generic Alternatives: The Curious Case of Duexis. JAMA Internal Medicine 2017, 177: 305-306. PMID: 28114637, DOI: 10.1001/jamainternmed.2016.8423.Commentaries, Editorials and Letters
2012
Regulatory Review of Novel Therapeutics — Comparison of Three Regulatory Agencies
Downing NS, Aminawung JA, Shah ND, Braunstein JB, Krumholz HM, Ross JS. Regulatory Review of Novel Therapeutics — Comparison of Three Regulatory Agencies. New England Journal Of Medicine 2012, 366: 2284-2293. PMID: 22591257, PMCID: PMC3504361, DOI: 10.1056/nejmsa1200223.Peer-Reviewed Original ResearchConceptsNovel therapeutic agentsEuropean Medicines AgencyHealth CanadaTherapeutic agentsNew therapeutic agentsMedian lengthTherapeutic comparisonsDrug AdministrationMedicines AgencyNew drug applicationsPrescription Drug User Fee ActNovel therapeuticsDrug applicationFDAUnique agentUnited StatesTotal review timeFirst reviewRegulatory agenciesReview timeDaysAgentsReviewRegulatory reviewVast majority